BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 17060941)

  • 21. PEA3, AP-1, and a unique repetitive sequence all are involved in transcriptional regulation of the breast cancer-associated gene, mammaglobin.
    Hesselbrock DR; Kurpios N; Hassell JA; Watson MA; Fleming TP
    Breast Cancer Res Treat; 2005 Feb; 89(3):289-96. PubMed ID: 15754128
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer.
    Shimizu C; Masuda N; Yoshimura K; Tsuda H; Mano M; Ando M; Tamura K; Fujiwara Y
    Jpn J Clin Oncol; 2009 Aug; 39(8):484-90. PubMed ID: 19477897
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
    D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
    Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of PEA3 and lack of correlation between PEA3 and HER-2/neu expression in breast cancer.
    Xia WY; Lien HC; Wang SC; Pan Y; Sahin A; Kuo YH; Chang KJ; Zhou X; Wang H; Yu Z; Hortobagyi G; Shi DR; Hung MC
    Breast Cancer Res Treat; 2006 Aug; 98(3):295-301. PubMed ID: 16752078
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer.
    Garcia-Recio S; Fuster G; Fernandez-Nogueira P; Pastor-Arroyo EM; Park SY; Mayordomo C; Ametller E; Mancino M; Gonzalez-Farre X; Russnes HG; Engel P; Costamagna D; Fernandez PL; Gascón P; Almendro V
    Cancer Res; 2013 Nov; 73(21):6424-34. PubMed ID: 24030979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients.
    Nagai MA; Gerhard R; Fregnani JH; Nonogaki S; Rierger RB; Netto MM; Soares FA
    Breast Cancer Res Treat; 2011 Feb; 126(1):1-14. PubMed ID: 20369286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma.
    Esteva FJ; Sahin AA; Smith TL; Yang Y; Pusztai L; Nahta R; Buchholz TA; Buzdar AU; Hortobagyi GN; Bacus SS
    Cancer; 2004 Feb; 100(3):499-506. PubMed ID: 14745865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression level of insulin-like growth factor binding protein 5 mRNA is a prognostic factor for breast cancer.
    Li X; Cao X; Li X; Zhang W; Feng Y
    Cancer Sci; 2007 Oct; 98(10):1592-6. PubMed ID: 17651454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer.
    Jensen JD; Knoop A; Ewertz M; Laenkholm AV
    Breast Cancer Res Treat; 2012 Apr; 132(2):511-21. PubMed ID: 21667123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of HER2 and its association with AP-2 in breast cancer.
    Pellikainen J; Naukkarinen A; Ropponen K; Rummukainen J; Kataja V; Kellokoski J; Eskelinen M; Kosma VM
    Eur J Cancer; 2004 Jul; 40(10):1485-95. PubMed ID: 15196531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The significance of c-erbB-2 overexpression and p53 expression in patients with axillary lymph node--negative breast cancer: a tissue microarray study.
    Ko SS; Na YS; Yoon CS; Park JY; Kim HS; Hur MH; Lee HK; Chun YK; Kang SS; Park BW; Lee JH
    Int J Surg Pathol; 2007 Apr; 15(2):98-109. PubMed ID: 17478762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alteration of REDD1-mediated mammalian target of rapamycin pathway and hypoxia-inducible factor-1α regulation in human breast cancer.
    Koo JS; Jung W
    Pathobiology; 2010; 77(6):289-300. PubMed ID: 21266827
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.
    Razis E; Kalogeras KT; Kotoula V; Eleftheraki AG; Nikitas N; Kronenwett R; Timotheadou E; Christodoulou C; Pectasides D; Gogas H; Wirtz RM; Makatsoris T; Bafaloukos D; Aravantinos G; Televantou D; Pavlidis N; Fountzilas G
    Clin Breast Cancer; 2012 Jun; 12(3):183-93. PubMed ID: 22607768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiogenic molecule expression is downregulated in effusions from breast cancer patients.
    Konstantinovsky S; Nielsen S; Vyberg M; Kvalheim G; Nesland JM; Reich R; Davidson B
    Breast Cancer Res Treat; 2005 Nov; 94(1):71-80. PubMed ID: 16142438
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relation between hemostatic parameters and prognostic/predictive factors in breast cancer.
    Yigit E; Gönüllü G; Yücel I; Turgut M; Erdem D; Cakar B
    Eur J Intern Med; 2008 Dec; 19(8):602-7. PubMed ID: 19046726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma.
    González LO; Corte MD; Junquera S; González-Fernández R; del Casar JM; García C; Andicoechea A; Vázquez J; Pérez-Fernández R; Vizoso FJ
    Hum Pathol; 2009 Sep; 40(9):1224-33. PubMed ID: 19439346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study.
    Bacman D; Merkel S; Croner R; Papadopoulos T; Brueckl W; Dimmler A
    BMC Cancer; 2007 Aug; 7():156. PubMed ID: 17692120
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SLP-2 overexpression could serve as a prognostic factor in node positive and HER2 negative breast cancer.
    Cao W; Zhang B; Li J; Liu Y; Liu Z; Sun B
    Pathology; 2011 Dec; 43(7):713-8. PubMed ID: 22081131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.
    Holm NT; Byrnes K; Li BD; Turnage RH; Abreo F; Mathis JM; Chu QD
    J Surg Res; 2007 Jul; 141(1):53-9. PubMed ID: 17574038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.